We are live on
!
Find out more
CAM
Cormorant Asset Management Portfolio holdings
AUM
$1.99B
1-Year Est. Return
737.95%
This Fund
S&P 500
This Quarter
Est. Return
+41.62%
1 Year Est. Return
+737.95%
3 Year Est. Return
+5,256.52%
5 Year Est. Return
+13,483.26%
10 Year Est. Return
+564,575.55%
AUM
$1.43B
AUM Growth
+$108M
(+8.2%)
Cap. Flow
-$133M
Cap. Flow
% of AUM
-9.27%
Top 10 Holdings %
Top 10 Hldgs %
45.41%
Holding
87
New
7
Increased
18
Reduced
17
Closed
14
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gossamer Bio
GOSS
|
+$37.2M |
| 2 |
APLS
Apellis Pharmaceuticals
APLS
|
+$31.2M |
| 3 |
ACLX
Arcellx
ACLX
|
+$29.2M |
| 4 |
Arcutis Biotherapeutics
ARQT
|
+$22.7M |
| 5 |
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
|
+$20.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
TPTX
Turning Point Therapeutics, Inc. Common Stock
TPTX
|
+$187M |
| 2 |
CCXI
ChemoCentryx, Inc.
CCXI
|
+$35.3M |
| 3 |
FMTX
Forma Therapeutics Holdings, Inc. Common Stock
FMTX
|
+$21.9M |
| 4 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
+$21.3M |
| 5 |
ITCI
Intra-Cellular Therapies Inc.
ITCI
|
+$15.7M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 99.37% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
VERV
26
DELISTED
Verve Therapeutics
VERV
| $20.6M | 1.44% |
600,000
-100,710
| -14% | -$3.21M |
|
27
Adicet Bio
ACET
$74.7M
| $19.9M | 1.39% |
87,500
-25,000
| -22% | -$6.35M |
|
|
28
Arcutis Biotherapeutics
ARQT
$3.18B
| $19.1M | 1.34% |
+1,000,000
| New | +$22.7M |
|
29
Amylyx Pharmaceuticals
AMLX
$2.54B
| $17.2M | 1.2% |
+610,000
| New | +$15.2M |
|
30
BioAtla
BCAB
$5.74M
| $16.8M | 1.17% |
43,622
+2,858
| +7% | +$936K |
|
31
Pliant Therapeutics
PLRX
$65M
| $16.4M | 1.14% |
782,788
+300,375
| +62% | +$5.75M |
|
|
VECT
32
DELISTED
VectivBio Holding AG Ordinary Shares
VECT
| $15.2M | 1.06% |
2,536,617
-303,772
| -11% | -$1.65M |
|
33
Tango Therapeutics
TNGX
$4.41B
| $14.9M | 1.04% |
4,116,949
-390,894
| -9% | -$1.67M |
|
34
BridgeBio Pharma
BBIO
$16.5B
| $14.6M | 1.02% |
1,469,179
| – | – |
|
35
Cytokinetics
CYTK
$10.4B
| $14.3M | 1% |
296,000
-104,000
| -26% | -$5.01M |
|
36
Stoke Therapeutics
STOK
$2.11B
| $14M | 0.98% |
1,087,807
| – | – |
|
37
Rocket Pharmaceuticals
RCKT
$394M
| $13.9M | 0.97% |
868,550
| – | – |
|
|
RAIN
38
DELISTED
Rain Oncology Inc. Common Stock
RAIN
| $11.4M | 0.79% |
2,326,660
| – | – |
|
|
ATXS
39
DELISTED
Astria Therapeutics
ATXS
| $10.8M | 0.76% |
1,200,000
+900,000
| +300% | +$6.03M |
|
40
Eli Lilly
LLY
$1.06T
| $9.7M | 0.68% |
+30,000
| New | +$9.51M |
|
41
Pharvaris
PHVS
$2.44B
| $9.26M | 0.65% |
1,207,500
+61,547
| +5% | +$962K |
|
|
ISEE
42
PUT
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $8.97M | 0.63% |
+500,000
| New | +$6.56M |
|
43
Atea Pharmaceuticals
AVIR
$420M
| $8.8M | 0.62% |
1,547,181
| – | – |
|
|
CNTA
44
DELISTED
Centessa Pharmaceuticals
CNTA
| $7.93M | 0.55% |
1,972,728
-954,545
| -33% | -$4.37M |
|
|
LBPH
45
DELISTED
Longboard Pharmaceuticals, Inc. Common Stock
LBPH
| $7.88M | 0.55% |
2,118,283
-154,938
| -7% | -$572K |
|
46
GH Research
GHRS
$2.08B
| $6.89M | 0.48% |
593,043
-15,080
| -2% | -$190K |
|
47
ALX Oncology
ALXO
$283M
| $6.82M | 0.48% |
712,079
| – | – |
|
48
Tyra Biosciences
TYRA
$1.58B
| $6.54M | 0.46% |
743,988
| – | – |
|
|
PSTX
49
DELISTED
Poseida Therapeutics, Inc. Common Stock
PSTX
| $6.53M | 0.46% |
+1,850,000
| New | +$6.12M |
|
50
IDEAYA Biosciences
IDYA
$3.56B
| $6.24M | 0.44% |
+418,320
| New | +$5.43M |
|
Similar funds
SC
RMCM
RCM
LGM
MYAM
C
TCM
BGM
Cormorant Asset Management's Q3 2022 Portfolio in Review
As of Q3 2022, Cormorant Asset Management held 87 positions worth $1.43B, up 8.2% from $1.32B the previous quarter. Its ten largest holdings account for 45% of the portfolio.
Cormorant Asset Management withdrew a net $133M in Q3 2022, closing 14 positions and reducing 17 holdings. Its most notable exit was Turning Point Therapeutics, Inc. Common Stock, an estimated $187M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 95% a quarter earlier.
Against the trend, Cormorant Asset Management opened a new position in Arcutis Biotherapeutics worth $19.1M.
- Cormorant Asset Management's largest Q3 2022 buy was Arcutis Biotherapeutics: 1,000,000 shares worth $19.1M.
- Cormorant Asset Management added most to Gossamer Bio in Q3 2022, an estimated $37.2M increase.
- Cormorant Asset Management's biggest Q3 2022 reduction was Design Therapeutics, cutting an estimated $9.95M.
- Cormorant Asset Management fully exited Turning Point Therapeutics, Inc. Common Stock in Q3 2022, selling an estimated $187M.
- Cormorant Asset Management's ten largest holdings make up 45% of its $1.43B portfolio in Q3 2022.
- Cormorant Asset Management opened 7 new positions and closed 14 in Q3 2022.
- Cormorant Asset Management's portfolio value rose 8.2% quarter-over-quarter to $1.43B.
Based on Cormorant Asset Management's 13F filing for Q3 2022, filed 14 Nov 2022.